BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33375775)

  • 21. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
    Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
    Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Germline CBL mutation associated with a noonan-like syndrome with primary lymphedema and teratoma associated with acquired uniparental isodisomy of chromosome 11q23.
    Hanson HL; Wilson MJ; Short JP; Chioza BA; Crosby AH; Nash RM; Marks KJ; Mansour S
    Am J Med Genet A; 2014 Apr; 164A(4):1003-9. PubMed ID: 24458550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Clinical Landscape of NRAS- mutated Juvenile Myelomonocytic Leukemia-like Myeloproliferation Includes Children With Costello Syndrome.
    Pabari R; Chun K; Naqvi A
    J Pediatr Hematol Oncol; 2023 Apr; 45(3):e401-e405. PubMed ID: 35665722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
    Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JMML genomics and decisions.
    Niemeyer CM
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
    Tüfekçi Ö; Ören H; Demir Yenigürbüz F; Gözmen S; Karapınar TH; İrken G
    Turk J Haematol; 2015 Jun; 32(2):175-9. PubMed ID: 26316488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune dysregulation associated with co-occurring germline CBL and SH2B3 variants.
    Baccelli F; Leardini D; Muratore E; Messelodi D; Bertuccio SN; Chiriaco M; Cancrini C; Conti F; Castagnetti F; Pedace L; Pession A; Yoshimi A; Niemeyer C; Tartaglia M; Locatelli F; Masetti R
    Hum Genomics; 2022 Sep; 16(1):40. PubMed ID: 36123612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.
    Sakaguchi H; Okuno Y; Muramatsu H; Yoshida K; Shiraishi Y; Takahashi M; Kon A; Sanada M; Chiba K; Tanaka H; Makishima H; Wang X; Xu Y; Doisaki S; Hama A; Nakanishi K; Takahashi Y; Yoshida N; Maciejewski JP; Miyano S; Ogawa S; Kojima S
    Nat Genet; 2013 Aug; 45(8):937-41. PubMed ID: 23832011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia.
    Doisaki S; Muramatsu H; Shimada A; Takahashi Y; Mori-Ezaki M; Sato M; Kawaguchi H; Kinoshita A; Sotomatsu M; Hayashi Y; Furukawa-Hibi Y; Yamada K; Hoshino H; Kiyoi H; Yoshida N; Sakaguchi H; Narita A; Wang X; Ismael O; Xu Y; Nishio N; Tanaka M; Hama A; Koike K; Kojima S
    Blood; 2012 Aug; 120(7):1485-8. PubMed ID: 22753870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A child with juvenile myelomonocytic leukemia possessing a concurrent germline CBL mutation and a NF1 variant of uncertain significance: A rare case with a common problem in the era of high-throughput sequencing.
    Wang WH; Lu MY; Tsai CH; Wang SC; Chou SW; Jou ST
    J Formos Med Assoc; 2021 Apr; 120(4):1148-1152. PubMed ID: 32933826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
    Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
    Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
    Locatelli F; Algeri M; Merli P; Strocchio L
    Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL.
    Gagne AL; Maguire JA; Gandre-Babbe S; Chou ST; Tasian SK; Loh ML; Weiss MJ; Gadue P; French DL
    Stem Cell Res; 2018 Aug; 31():157-160. PubMed ID: 30096712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How I treat juvenile myelomonocytic leukemia.
    Locatelli F; Niemeyer CM
    Blood; 2015 Feb; 125(7):1083-90. PubMed ID: 25564399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transient immune deficiency accompanied with homozygous CBL rare variant.
    Morishita A; Yeh TW; Tomari K; Furuichi M; Kashimada K; Morio T; Takagi M; Imai K
    Pediatr Int; 2023 Jan; 65(1):e15439. PubMed ID: 36495474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients.
    Coppe A; Nogara L; Pizzuto MS; Cani A; Cesaro S; Masetti R; Locatelli F; Te Kronnie G; Basso G; Bortoluzzi S; Bresolin S
    Hum Mutat; 2018 Apr; 39(4):579-587. PubMed ID: 29316027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
    Yoshida N; Doisaki S; Kojima S
    Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term survival after nonintensive chemotherapy in some juvenile myelomonocytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations.
    Matsuda K; Taira C; Sakashita K; Saito S; Tanaka-Yanagisawa M; Yanagisawa R; Nakazawa Y; Shiohara M; Fukushima K; Oda M; Honda T; Nakahata T; Koike K
    Blood; 2010 Jul; 115(26):5429-31. PubMed ID: 20595524
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical and molecular features of
    Yoshida T; Muramatsu H; Wakamatsu M; Sajiki D; Murakami N; Kitazawa H; Okamoto Y; Taniguchi R; Kataoka S; Narita A; Hama A; Okuno Y; Takahashi Y
    Haematologica; 2023 Nov; 108(11):3115-3119. PubMed ID: 37226702
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.